BONTAC NAD Products Receive Widespread Acclaim from Customers at Exhibitions in Germany and the United States
Recently, BONTAC Biotech has made frequent appearances on the international stage. Following its successful participation in Hi Japan in Tokyo, the company once again shined at two major global events — CPHI Frankfurt in Germany and SupplySide Global in Las Vegas, USA — successfully concluding its 2025 overseas exhibition journey.
As a pioneer and leading enterprise in the NMN industry, BONTAC Biotech showcased its craftsmanship-driven raw materials, full-chain R&D technology, and one-stop product solutions, presenting to global customers its commitment to high quality, advanced technology, and premium service.
During the two international exhibitions in Germany and the United States, BONTAC Biotech comprehensively displayed its full range of NAD⁺ precursor products, including key coenzyme materials such as NMN, NMNH, and NR, as well as steviol glycosides RebD/RebM, natural sweeteners that drew significant attention from international visitors.
It is worth mentioning that BONTAC Biotech, the world’s first national-level “Little Giant” enterprise to achieve mass production of both NMN and NMNH, currently holds 24 NMN-related invention patents, ranking first globally in patent ownership. The company’s proprietary Bonpure® seven-step purification technology ensures that the purity of NMN consistently remains above 99.5%. Notably, the raw materials used in the landmark NMN anti-aging study published in the top-tier international journal Cell in 2018 were supplied by BONTAC Biotech, underscoring the company’s technical authority and leadership within the industry.
In terms of innovation, BONTAC Biotech was the first in the world to obtain an invention patent for NMNH crystals, positioning it as a new and highly efficient NAD⁺ precursor. The company also successfully secured invention patents for NR crystals in both China and the United States, further solidifying its leading position in the coenzyme raw material field.
In the natural products sector, steviol glycosides RebD/RebM, produced using a full-enzyme catalytic process, offer advantages such as low cost, high sweetness, low calories, and a sucrose-like pure taste, making them an ideal alternative to traditional sugars. Also featured at the exhibitions were high value-added coenzyme materials including NAD, NADP, and NADH, as well as rare ginsenosides such as Rh2 and Rg3. These products precisely meet the international market’s growing demand for healthy, natural, and high-standard ingredients.
As a pioneer and leading enterprise in the NMN industry, BONTAC Biotech showcased its craftsmanship-driven raw materials, full-chain R&D technology, and one-stop product solutions, presenting to global customers its commitment to high quality, advanced technology, and premium service.
During the two international exhibitions in Germany and the United States, BONTAC Biotech comprehensively displayed its full range of NAD⁺ precursor products, including key coenzyme materials such as NMN, NMNH, and NR, as well as steviol glycosides RebD/RebM, natural sweeteners that drew significant attention from international visitors.
In terms of innovation, BONTAC Biotech was the first in the world to obtain an invention patent for NMNH crystals, positioning it as a new and highly efficient NAD⁺ precursor. The company also successfully secured invention patents for NR crystals in both China and the United States, further solidifying its leading position in the coenzyme raw material field.
In the natural products sector, steviol glycosides RebD/RebM, produced using a full-enzyme catalytic process, offer advantages such as low cost, high sweetness, low calories, and a sucrose-like pure taste, making them an ideal alternative to traditional sugars. Also featured at the exhibitions were high value-added coenzyme materials including NAD, NADP, and NADH, as well as rare ginsenosides such as Rh2 and Rg3. These products precisely meet the international market’s growing demand for healthy, natural, and high-standard ingredients.
Amid the global wave of innovation and transformation in the health industry, green biotechnology is becoming a key driving force for promoting sustainable development and addressing health challenges. With the successful conclusion of its three international exhibitions, BONTAC Biotech will continue to increase R&D investment, expand its product portfolio and service capabilities, and remain committed to providing global customers with higher-quality, more efficient, and environmentally friendly raw materials and solutions—working together to create a healthier future for all.
.jpg?imageView2/1/w/360/h/200)
